| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 780.76M | 647.04M | 508.69M | 324.52M | 222.56M | 110.64M |
| Gross Profit | 570.97M | 468.32M | 358.23M | 218.05M | 153.18M | 77.83M |
| EBITDA | 140.50M | 125.43M | 82.92M | 32.07M | 23.52M | 20.92M |
| Net Income | 110.16M | 101.49M | 58.53M | 21.73M | 13.92M | 11.71M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 438.88M | 404.91M | 216.41M | 142.97M | 81.75M |
| Cash, Cash Equivalents and Short-Term Investments | 639.71M | 100.22M | 115.65M | 40.95M | 28.83M | 39.77M |
| Total Debt | 23.84M | 22.71M | 12.51M | 15.88M | 5.35M | 5.49M |
| Total Liabilities | 728.45M | 156.58M | 121.80M | 117.70M | 74.32M | 29.40M |
| Stockholders Equity | 380.68M | 282.30M | 283.11M | 98.70M | 68.65M | 52.35M |
Cash Flow | ||||||
| Free Cash Flow | 102.09M | 129.76M | 81.84M | 31.25M | 3.12M | 19.75M |
| Operating Cash Flow | 108.70M | 137.76M | 87.45M | 39.03M | 9.87M | 23.02M |
| Investing Cash Flow | -46.45M | 1.35M | -139.99M | -25.78M | -18.78M | 6.67M |
| Financing Cash Flow | 443.82M | -127.30M | 48.81M | -246.00K | -318.00K | 161.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $2.43B | 23.68 | 29.74% | ― | 25.80% | 10.73% | |
73 Outperform | $4.06B | 18.01 | ― | ― | 14.20% | 204.86% | |
69 Neutral | $2.06B | 30.47 | 9.79% | ― | 10.58% | -45.52% | |
66 Neutral | $4.10B | 56.03 | 20.46% | ― | 18.37% | ― | |
65 Neutral | $2.73B | ― | 0.58% | ― | 24.71% | 99.52% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | $3.17B | ― | -8.95% | ― | 11.05% | 45.23% |
On November 19, 2025, ODDITY Tech Ltd. announced its financial results for the third quarter ending September 30, 2025, reporting a record net revenue of $148 million, a 24% increase year-over-year. The company exceeded its financial guidance across all metrics and launched METHODIQ, a new brand targeting the medical care system. With a strong cash position and ongoing investments in technology and brand development, ODDITY is well-positioned for future growth, leading to an increased financial outlook for the full year.
On November 18, 2025, ODDITY Tech Ltd. announced the launch of METHODIQ, a telehealth platform designed to transform medical care through AI-driven, customized treatments. METHODIQ initially targets dermatology, addressing conditions like acne, hyperpigmentation, and eczema, affecting millions of Americans. The platform aims to provide high-efficacy treatments accessible online, eliminating the need for traditional doctor visits. Developed with board-certified dermatologists, METHODIQ integrates AI-powered skin analysis and progress tracking to offer personalized care. This launch represents a significant expansion for ODDITY, leveraging its technology and direct-to-consumer model to enter the medical care market, promising long-term growth potential.
On November 13, 2025, ODDITY Tech Ltd. held its Annual General Meeting of Shareholders in Tel Aviv-Jaffa, Israel. During the meeting, shareholders approved all proposals in accordance with Israeli Companies Law and the company’s amended articles of association, which were outlined in the proxy statement submitted to the SEC on September 30, 2025.
ODDITY Tech Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for November 13, 2025, in Tel Aviv-Jaffa, Israel. The meeting will involve voting on key proposals, including the re-appointment of its independent registered public accounting firm and the re-election of a board director. Shareholders of record as of October 6, 2025, are entitled to vote, and the company encourages participation either in person or through proxy voting. This meeting is significant for stakeholders as it will address important governance issues and potentially impact the company’s strategic direction.